ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 806

Association of a Single Nucleotide Polymorphism (SNP) in IL-12B Region with Clinical Features and Peripheral T Cell Profiles of Patients with Takayasu Arteritis

Toshiki Nakajima1, Hajime Yoshifuji1, Chikashi Terao2, Koji Kitagori1, Ran Nakashima1, Yoshitaka Imura3, Naoichiro Yukawa1, Koichiro Ohmura1, Takao Fujii1 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Center for Genomic Medicine, Kyoto University, Kyoto, Japan, 3Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: IL-23, T cells and takayasu arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

We preliminarily found a SNP (A vs. C, rs6871626) in IL-12B region as a susceptibility gene to Takayasu arteritis (TAK) by genome-wide association study. IL-12Bencodes IL-12/IL-23 p40 that regulates differentiation and activation of Th1 and Th17. In the present study, we investigated the association of this SNP with clinical characteristics and pathophysiology of TAK.

Methods

We investigated 1) the association of the SNP with clinical features of 84 TAK patients who have visited Kyoto University Hospital and 2) the association of the SNP with expression levels of surface markers and intracellular cytokines in peripheral T cells sampled from 21 TAK patients and 15 healthy controls (HC). We obtained peripheral blood mononuclear cells from the TAK patients and HC, stained them with fluorescent antibodies, and analyzed them with flow cytometry.

Results

1) In 84 patients with TAK, 68 were the risk group (R-Group; AA+AC) and 16 were the non-risk group (NR-Group; CC). The complication rate of aortic regurgitation (AR) was 51% in R-Group, significantly higher than 13% in NR-Group (p<0.01). The ultrasound-evaluated severity of AR was higher in R-Group (p<0.01). eGFR tended to be lower in R-Group than in NR-Group (70.5 vs. 80.3 mL/min/1.73m2 , p=0.2). The complication rate of abdominal arterial lesions was 58% in R-Group, significantly higher than 27% in NR-Group (p<0.05). 2) In 21 patients with TAK analyzing T cells, 14 and 7 were R-Group and NR-Group, respectively. In CD4+ T cells, CXCR3+ (Th1) cells were 6.9% in patients (7.5% in R-Group and 5.7% in NR-Group), tended to be higher than 5.7% in HC (p=0.16), while CCR6+ (Th17) cells were 16.0% in patients (16.5% in R-Group and 15.4% in NR-Group), significantly higher than 8.3% in HC (p<0.01). In CD4+ T cells, IFN-γ+ cells in R-Group was significantly higher than in NR-Group (23% vs.7%, p=0.02), while IL-17+cells were not significantly different between R-Group and NR Group (0.7% vs. 1.4%, p=0.37).

Conclusion

In TAK patients with the risk allele of IL-12B, the complications of aortic valve and abdominal arteries were more frequent than in patients with the non-risk allele. TAK patients showed a tendency to have higher percentage of Th1 and Th17 cells than HC, and R-group had higher percentage of Th1 cells than NR-Group. The results suggested a possibility that this SNP may be involved in the pathophysiology of TAK through increased expression of cytokines.


Disclosure:

T. Nakajima,
None;

H. Yoshifuji,
None;

C. Terao,
None;

K. Kitagori,
None;

R. Nakashima,
None;

Y. Imura,
None;

N. Yukawa,
None;

K. Ohmura,
None;

T. Fujii,
None;

T. Mimori,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-a-single-nucleotide-polymorphism-snp-in-il-12b-region-with-clinical-features-and-peripheral-t-cell-profiles-of-patients-with-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology